Speaker: Dr. W. Frank An;

Sr. Director of Antibody Therapeutics;

• Immunologic and inflammatory (I&I) diseases, including autoimmune conditions, affect more than 10% of the global population. Despite recent significant clinical advances in disease management, considerable unmet medical needs remain, and more effective, safer therapeutics are critically needed.
• Biocytogen’s antibody discovery platform leverages the fully human transgenic RenMice platform, which delivers both early-stage antibody binders and well-characterized preclinical candidate antibodies for I&I and autoimmune indications.
• The webinar will introduce Biocytogen’s proprietary antibody discovery platforms and illustrate how they are utilized in the identification of monoclonal and bispecific antibodies targeting proteins involved in immunological disorders.